Amgen-Horizon deal shouldn't be enjoined pending US FTC review because of lack of overlaps, trade groups tell court
MLex Summary: Enjoining the merger of Amgen and Horizon pending a US Federal Trade Commission administrative trial is unnecessary because the lack of overlap between the two firms means "post-merger relief will...To view the full article, register now.
Already a subscriber? Click here to view full article